Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma

Summary

This is a open-label, dose escalation, multi-center, Phase I / Phase II study to assess the safety of an autologous T-cell product (ET140202) in adult subjects with advanced Alpha-fetoprotein (AFP) positive/Human Leukocyte Antigen (HLA) A-2 positive Hepatocellular Carcinoma (HCC).

Timeline

Start

2019-05-30

Primary completion

2020-12-31

Completion

2020-12-31

Outcome

Outcome not reported

Stopped: “Reallocation of resources to new HCC study.”

Drugs

Indications